Jazz Pharmaceuticals plc announced a definitive agreement to acquire privately-held Actio Biosciences for an $820 million upfront payment and up to $500 million in contingent consideration. The transaction adds ABS-1230, a clinical-stage KCNT1 inhibitor for rare epilepsy, to Jazz's portfolio. The deal is expected to close by the fourth quarter of 2026, subject to customary conditions. This acquisition expands Jazz Pharmaceuticals' leadership in rare and severe epilepsies.
